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Abstract: 
A number of vascular risk factors and vascular diseases contribute to cognitive impairment and 
dementia. Many studies and registries show an association of atrial fibrillation (AF) with 
cognitive impairment, cognitive decline and dementia. This is true for vascular dementia and 
Alzheimer's disease. The assumed multifactorial mechanisms include ischemic stroke, both 
apparent and silent, cerebral micro-infarcts, cerebral hemorrhage and reduced cerebral blood 
flow. A number of retrospective observational and prospective studies support that 
anticoagulation in patients with AF may reduce the risk of cognitive decline and dementia. This 
holds for both vitamin-K antagonists (VKA, e.g. warfarin) and non-vitamin-K antagonist oral 
anticoagulants (NOACs).  However, it still remains unproven, that anticoagulation reduces 
cognitive decline and dementia in AF patients, based on randomised trials. 
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Condensed Abstract: Studies and registries show an association of atrial fibrillation (AF) with 
cognitive impairment, cognitive decline and dementia. The assumed mechanisms include 
ischemic stroke, both overt and silent, cerebral micro-infarcts and reduced cerebral blood flow. 
Anticoagulation in patients with AF may reduce the risk of cognitive decline and dementia, 
however this remains unproven, based on randomised trials. 
 
 
Abbreviations:  
AD = Alzheimer’s disease 
AF = atrial fibrillation 
CMB = cerebral micro-bleeds 
HR = hazard ratio 
ICH = intracerebral hemorrhage 
INR = international normalized ratio 
MMSE = Mini Mental State Examination 
NOAC = non-vitamin-K oral anticoagulant 
OAC = oral anticoagulant 
OR = odds ratio 
RR = relative risk 
SD = senile dementia  
TIA = transient ischemic attack 
TTR = time in therapeutic range 
VD = vascular dementia 
  
4 
Atrial fibrillation (AF) and dementia are predominantly diseases of elderly people. The 
incidence of AF and cognitive decline increases with advanced age, and the co-occurrence of 
these two frequent conditions might be explained by a common factor such as increasing age. A 
number of studies, however, indicate that vascular risk factors and vascular diseases not only 
contribute to vascular dementia but also to degenerative dementias such as Alzheimer’s disease 
(1, 2). Importantly, AF increases the risk of stroke five-fold and stroke is an important risk factor 
and predictor of cognitive decline and dementia (3). Thus, a number of studies have indicated 
that the presence of AF might accelerate the risk of cognitive decline and dementia, even in 
patients without prior stroke.  
This review article will provide an overview of the current knowledge on the relationship 
between AF, cognitive impairment and decline, and dementia and the possible role of 
anticoagulation for the prevention of dementia in patients with AF. 
Is AF associated with cognitive impairment, cognitive decline, and dementia? 
A number of prospective and retrospective studies have investigated the relationship 
between AF, cognitive decline and dementia (Table 1). The prospective Intermountain Heart 
Collaborative Study database evaluated 37,025 consecutive patients followed up them for a mean 
of 5 years for the development of AF and dementia (4). In this cohort 10,161 (27%) patients 
developed AF and 1,535 (4.1%) developed dementia - importantly AF was independently 
associated with all dementia types, with the highest risk in the younger group (<70 years). A 
posthoc-analysis of the ONTARGET and TRANSCEND studies  showed that AF was associated 
with an increased risk of cognitive decline (hazard ratio [HR] 1.14, 95% confidence interval [CI] 
1.03-1.26), new onset dementia (HR 1.30, 95% CI 1.14-1.49), loss of independence in 
performing activities of daily living (HR 1.35, 95% CI 1.19-1.54) and admission to long-term 
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care facilities (HR 1.53, 95% CI 1.31-1.79) (5). 
The prospective Rotterdam study followed 6,514 dementia-free participants from 1989 to 
2010 (6). and found that Prevalent AF increased the risk of dementia (HR 1.33; 95% CI 1.02-
1.73). Among 6,196 participants without prevalent AF during 79,003 person-years of follow-up, 
723 participants (11.7%) developed incident AF and 932 individuals (15.0%) developed 
dementia. As with other studies above, AF was associated with an increased risk of dementia in 
younger participants (<67 years). The Whitehall II study recruited 10,308 persons aged 33-45 
years between 1985 and 1988 and followed them until 2013 (7). In this cohort incident dementia 
was more frequent in patients with AF compared to persons without AF (HR 1.87, 95% CI 1.37-
2.55).  
The relationship between AF and dementia is also evident from Asia.  For example, a 
study from Taiwan identified 332,665 AF subjects without dementia from the "National Health 
Insurance Research Database". Found that patients with AF had a higher risk of dementia (HR 
1.42, 95% CI 1.40-1.45) after adjustment for age, gender, baseline differences and medication 
use (8).  
The relationship between AF, cognitive impairment and dementia was also shown in 
ameta-analysis. Kalantarian et al. (9) identified 21 studies with 89,907 participants and 
investigated the association of AF with cognitive decline and dementia. AF was significantly 
associated with a higher risk of cognitive impairment independent of a history of stroke (RR 
1.34, 95% CI 1.13-1.58) (Table 2).The risk of dementia was also significantly increased (RR 
1.38, 95% CI 1.22-1.56) (Table 2).  
In summary, there is strong evidence from many prospective registries and studies that 
AF is associated with cognitive impairment, cognitive decline and dementia. This is also true for 
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patients without prior stroke. Such an association, however, does not necessarily imply a causal 
relationship, as there is very likely a multifactorial interaction with various cardiovascular risk 
factors involved, e.g. blood pressure control and renal function changes. The AF patient’s risk 
profile is also dynamic and many risk factors change over time (10, 11); many of the reported 
associations are based on baseline risk and have not tracked temporal changes in risk. 
Is AF associated with Alzheimer’s disease or vascular dementia? 
Alzheimer's disease and vascular dementia are by far the most common subtypes of 
dementia. Based on postmortem findings in relatively younger patients, Alzheimer's disease is 
characterized by neurodegenerative changes in the brain like amyloid depositions and 
neurofibrillary tangles. In the last decades accumulating evidence has established that stroke and 
cardiovascular disease are important risk factors not only of vascular dementia but also of 
Alzheimer's disease (4, 12-20).  
Pre-clinical markers of cerebrovascular disease, which can be visualized with various 
imaging techniques, such as intima media thickness of the carotid artery and white matter lesions 
and lacunar infarcts in the brain, have likewise been related to Alzheimer's disease (17, 20-22). 
Besides cardiovascular disease, conventional vascular risk factors, such as hypertension, diabetes 
mellitus and smoking, have also been associated with an increased risk of Alzheimer's disease 
(23, 24). The similarity of the presumed underlying pathophysiology of vascular dementia and 
Alzheimer's disease is clinically relevant, as treatment of cardiovascular disease and vascular risk 
factors may potentially prevent a significant proportion of dementia cases, a disease for which no 
treatment is currently available (25). 
The population-based Rotterdam Study previously showed that AF was more prevalent in 
participants with dementia (26) and a stronger association for Alzheimer's disease compared to 
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vascular dementia; however, the cross-sectional design of this study does not allow conclusions 
regarding a possible causal relationship. More recently, the Rotterdam Study explored the 
longitudinal relationship between AF and the risk of dementia, separately for prevalent and 
incident AF, and for all-cause dementia and Alzheimer's disease (6). In this cohort. Alzheimer’s 
disease occurred in 787 of 994 (79%) participants with prevalent AF and in 741 of 932 (79%) 
with incident AF. For both prevalent and incident AF, associations were only slightly attenuated 
when Alzheimer's disease was separately investigated - in persons with prevalent AF, the HRs 
for all-cause dementia was 1.33 (95% CI 1.02-1.73) versus a non-significant 1.29 (95% CI 0.95-
1.75) for Alzheimer's disease, and in those with incident AF, the HRs were non-significant  for 
all-cause dementia 1.23 (95% CI 0.98-1.56) versus 1.18 (95% CI 0.91-1.54) for Alzheimer's 
disease.  
Since dementia gradually develops over many years, AF probably needs to develop at a 
younger age to contribute to the neuropathology of underlying dementia, i.e. the typical 
Alzheimer changes or vascular lesions or both. Associations of other vascular risk factors of 
dementia, such as hypertension, hypercholesterolemia, and obesity also appear to differ with age; 
these elements are risk factors for dementia only when diagnosed earlier in life (27-29).  
Similarly, if AF is a causal factor in the etiology of dementia, one would expect that the 
longer a person suffers from this condition, the higher the risk of dementia would be. Indeed, the 
Rotterdam Study demonstrated that the risk of either all-cause dementia or Alzheimer's disease 
was highest for people who suffered the longest duration of AF, although this dose-response 
relationship was only present in younger participants. In contrast, a Finnish study concluded that 
the presence of AF in mid-life was not a risk factor of subsequent dementia, whereas late-life AF 
was (30); however, survival bias might have influenced these results, because only persons who 
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survived until a late re-examination were included in the study.  
In summary, AF probably increases the risk of both vascular dementia and Alzheimer’s 
disease, however the relationship to dementia is most probably stronger when AF starts at middle 
age and with a longer-duration of AF. 
What are the mechanisms leading to cognitive decline and dementia in patients with AF? 
AF-associated cognitive decline occurs even in the absence of clinical strokes. Clinically 
recognized strokes are only the tip of the iceberg of AF-induced brain ischemia. Covert (i.e. 
silent) brain infarcts detected by neuroimaging in AF patients are more frequent than clinical 
strokes (31) and are associated with cognitive dysfunction (32) (Table 3). In addition to 
macroscopic covert brain infarcts, smaller cerebral micro-infarcts (beyond the resolution of 
conventional neuroimaging) are linked to cognitive impairment (33) and AF is an independent 
risk factor for such cerebral micro-infarcts (34).  Indeed, the Atherosclerosis Risk in 
Communities Study observed that cognitive decline in patients with AF was only observed in 
those who had subclinical cerebral infarcts (35). Hence, unrecognized embolism is a plausible 
mechanism underlying AF-associated cognitive impairment and dementia. 
Reduced cardiac output in the absence of clinical heart failure is associated with reduced 
cerebral blood flow in the elderly, particularly blood flow to the temporal lobes (36) and this has 
been associated with incident dementia, including Alzheimer's disease (37). AF is associated 
with reduced cardiac output and cerebral blood flow (38, 39), and chronic cerebral 
hypoperfusion could play a role (which is unresponsive to anticoagulation) in AF-associated 
cognitive decline. If so, then efforts to re-establish sinus rhythm could have a beneficial effect on 
cognition – at least theoretically. In the largest randomized trial so far, assignment to rhythm 
control had no benefit on cognition, but this was potentially confounded by unequal use of 
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anticoagulation (39). This is being further assessed in a large ongoing randomized controlled trial 
(EAST) (40). Other potential mechanisms also warrant consideration (Table 4). 
On balance, subclinical embolic brain ischemia (covert brain infarcts, cerebral micro-
infarcts) is likely to account for most of the cognitive deterioration associated with AF, but until 
further established by response to anticoagulants based on randomized trials, (for example, 
BRAIN-AF NCT02387229) this remains unproven. 
How might treatment of AF decrease the risk of cognitive decline and dementia? 
If we assume that dementia and AF are associated we can perhaps assume that 
anticoagulation might reduce the risk of cognitive decline and incident dementia in patients with 
AF.  
There is some suggestive evidence from observational studies that anticoagulation of AF 
patients (and good time in therapeutic range (TTR) with warfarin anticoagulation) is associated 
with reduced cognitive decline (41), supporting the contribution of embolism to cognitive 
impairment. However, potential confounding in these observational studies limits confidence in a 
cause-effect relationship.  
One randomized trial did not report a difference in cognition between AF patients treated 
with warfarin versus aspirin during 2.7 years of follow-up, but assessment of cognition was 
insensitive for decline (42). Another small prospective longitudinal cohort study in the UK did 
not find an effect of antithrombotic therapy in patients with AF on cognitive function (43). 
A systematic review of 19 studies assessed the association between cognitive impairment 
and AF thromboprophylaxis (44). One randomized controlled trial, comparing anticoagulation 
against antiplatelet therapy and change in MMSE score from baseline to last follow-up (maximal 
duration: 5.9 years) suggested a nonsignificant difference perhaps favoring anticoagulation 
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(mean difference: 0.90, 95% CI: 0.29-1.51). Another randomized controlled trial found a mean 
difference in MMSE score of 0.80 (95% CI: -0.07 to 1.67) in favor of anticoagulation.  The 
pooled odds ratio (OR) suggested no association with incident dementia, when comparing 
anticoagulant to antiplatelet therapy (two studies, Odds Ratio (OR): 1.23, 95% CI: 0.80-1.91) or 
no treatment (three studies, OR: 0.89, 95% CI: 0.47-1.69). Thus, there was no definitive 
evidence of cognitive benefit or harm from anticoagulation.  
When VKAs are used as thromboprophylaxis, the efficacy and safety are closely related 
to the quality of anticoagulation control, as reflected by the average TTR(45). This is relevant to 
the impact on dementia. For example, decreasing categories of percentage TTR were associated 
with increased dementia risk (vs TTR>75%)  as follows: <25%: HR 5.34, P < .0001; 26%-50%: 
HR 4.10, P < .0001; and 51%-75%: HR 2.57, P = .001(46).  
The Olmsted County population-based study also investigated the association of TTR 
during warfarin therapy and risk of dementia in 2800 non-demented AF patients (41). Incident 
dementia diagnosis occurred in 357 patients (12.8%) over a mean follow-up of five years. After 
adjusting for confounders, warfarin therapy was associated with a reduced incidence of dementia 
( HR 0.80; 95% CI, 0.64-0.99); however, only those in the 2 highest quartiles of TTR were 
associated with lower risk of dementia. Overall, better quality of anticoagulation management 
represented as percentage TTR among AF patients without dementia seems to be associated with 
lower dementia incidence.  
In recent years, the NOACs have changed the landscape of stroke prevention in AF, with their 
increasing use in many countries compared to warfarin (47). The question arises as to whether 
NOAC use may be associated with a lower risk of new-onset dementia compared to warfarin. In 
a propensity-matched analysis, patients taking NOAC were 43% less likely to develop 
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stroke/TIA/dementia than those taking warfarin but this difference was non-significant (HR 0.57; 
95% CI 0.17 - 1.97; p = 0.38)(48). 
Further, a retrospective registry study of all patients with hospital diagnosis of AF and no 
previous diagnosis of dementia in Sweden between 2006 and 2014 investigated the possible 
impact of anticoagulation on the incidence of dementia in patients with AF (49). Propensity 
score matching, falsification endpoints, and analyses according to intention-to-treat as well as 
on-treatment principles were used, and the study included 444,106 patients and over 1.5 million 
person years at risk. Patients without prior stroke on anticoagulant treatment at baseline had a 
29% lower risk of dementia than patients without anticoagulant treatment (HR 0.71, 95% CI 
0.68-0.74) with a 48% lower risk when analyzed on treatment (HR 0.52, 95% CI 0.50-055). 
Direct comparisons between NOACs and warfarin showed no significant difference.  
A possible mechanism underlying the observed benefit of anticoagulation could be the 
prevention of cerebral micro-emboli and silent brain infarcts. The benefit of OAC treatment was 
more pronounced among patients in whom treatment had been initiated early after the first 
diagnosed AF episode suggesting that there could be a dose-response relationship between 
unprotected time in AF and development of dementia. There was also a trend towards more 
benefit from treatment in patients with higher CHA2DS2-VASc scores supporting the notion that 
micro-embolization might be a cause of dementia in AF patients.  
In summary, we have only indirect evidence that effective anticoagulation in AF reduces 
the risk of cognitive impairment and dementia. Nevertheless, these observational results are 
supportive in arguing for the initiation of prospective clinical trials on the possible benefit of 
anticoagulation in AF for the prevention of cognitive decline and dementia.  
Impact of rhythm control 
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Cardioversion or AF ablation may result in sinus rhythm and improve cardiac output and 
cerebral perfusion. In the Intermountain AF study, for example, Bunch et al (50) compared 4,212 
consecutive patients who underwent AF ablation to 16,848 age/gender matched controls with AF 
(no ablation) and 16,848 age/gender matched controls without AF, who were followed up for at 
least 3 years. Of the 37,908 patients, Alzheimer's dementia occurred in 0.2% of the AF ablation 
patients compared to 0.9% of the AF non-ablation patients and 0.5% of the non-AF patients (P < 
0.0001). Other forms of dementia were also reduced significantly in AF patients treated with 
ablation.  
Prospective randomized trials investigating the potential benefit of rhythm control or 
cardioversion in AF would need to run for at least 10 years to show an impact on cognitive 
decline and dementia, and would require many thousands of patients. Therefore, it is unlikely 
that such trials will ever be funded.  
Practical considerations 
Elderly patients with AF and cognitive impairment can be difficult to treat with oral anti-
coagulation. Anticoagulation should only be initiated and maintained if a family member/carer or  
nurse supervises drug intake.  In the case of VKAs, adequate INR control and continued adher-
ence with therapy is required to avoid adverse outcomes (51, 52). With the NOACs, drug adher-
ence is crucial given the relatively short half-life of these drugs (53). 
Another unresolved practical issue is the question of whether anticoagulation should be 
introduced in AF patients with CHA2DS2-VASc score of 0-1 in males or 1-2 in females who 
have covert (i.e. silent) brain infarcts detected by neuroimaging performed due to various clinical 
indications or in patients with mild cognitive decline (no previous stroke or transient ischemic 
attack) or not. If silent infarcts show an “embolic” pattern (e.g. multiple infarcts in different vas-
13 
cular territories) this appearance might justify anticoagulation use (35). Considering the relative-
ly weak evidence that anticoagulation in AF prevents the progression from cognitive impairment 
to dementia, we would not recommend anticoagulation in these patients simply for the preven-
tion of dementia at the present time. 
Patients with cognitive impairment and dementia also have a higher risk of falls (54).  
While a very high risk of falls might constitute a contraindication for anticoagulation, it has been 
estimated that a patient would need to fall 295 times per year for the benefits of ischemic stroke 
reduction with anticoagulation to be outweighed by serious bleeding risks (55). The present 
availability of a specific reversal agent for dabigatran (Idaruzicumab) (54) and andexanet alfa for 
antiXa inhibitors  (56) where available, makes the management of NOAC-induced major 
hemorrhage or injury much easier (57). 
 
Conclusions 
A number of recent epidemiological studies have reported an association of AF with 
cognitive impairment, cognitive decline, and dementia. The risk of dementia was increased both 
for total dementia and Alzheimer’s disease with HRs ranging from 1.03 to 2.9, with the 
association between AF and dementia being strongest for patients aged <65 years. The increased 
risk of dementia was seen for vascular as well as Alzheimer's disease, but this is perhaps 
unsurprising since dementia and AF share a number of common vascular risk factors such as 
hypertension, heart failure, diabetes and lipid disorders. Other common risk factors include age, 
obesity and physical inactivity. Also, silent strokes and micro-bleeds are more common in 
patients with AF than in patients in sinus rhythm.  
In our view, the data are sufficient to regard AF as an independent cardiovascular risk 
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factor for accelerated cognitive impairment and dementia. Clinical stroke is only part of the story 
of AF-associated brain ischemia; the most likely mechanism linking AF and cognitive 
impairment is covert embolism to the brain causing silent (macro) brain infarcts and cerebral 
micro-infarcts. Chronic cerebral hypoperfusion is also plausible. While it is tempting to justify 
initiation of anticoagulation, it remains unproven thus far that anticoagulation (which is so 
effective for reducing clinical stroke) also reduces cognitive decline and dementia in AF patients. 
This is currently being investigated in a number of ongoing clinical trials. 
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Figure Legends 
Figure 1: Relationship between atrial fibrillation, cognitive decline and dementia via differ-
ent mechanisms. (adapted from Kalantarian & Ruskin, Cardiol Clin 2016)(58). Atrial fibrilla-
tion can lead by a number of mechanisms to thrombus formation in the left atrial appendage and 
cause clinical stroke or silent stroke. Both lead to morphological changes in the brain promoting 
cognitive decline or dementia. Genetic factors can contribute to both, dementia and atrial fibrilla-
tion. A number of vascular diseases and vascular risk factors have been associated with cognitive 
decline and dementia. 
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Table 1 
Association of AF with cognitive impairment or dementia. Results from 5 prospective 
registries. Odds ratios and (95% confidence intervals) 
 
Study N Follow-up 
(Years) 
Cognitive Decline Dementia 
Bunch et al (4) 37025 5  1.06-1.73* 
Marzona et al. (5) 31506 5 1.14 (1.03-1.26) 1.30 (1.14-1.54) 
De Bruijn et al. (6) 6514 21  1.33 (1.02-1.73) 
Sing-Manoux et al. 
(7) 
10308 15 1.87 (1.37-2.55)  
Liao et al (8) 332665 15  1.42 (1.40-1.45) 
*Odds ratios across 4 subgroups of dementia;  95% CI not provided 
 
Table 2 
Association of AF with cognitive impairment or dementia. Results from a meta-analysis of 14 
studies with 31506 AF patients and controls (9). RR = relative risk 
 
Parameter N studies RR (95% CI) 
Association between AF and cognitive 
impairment with or without stroke 
14 1.40 1.19-1.64 
Association between AF and dementia 8 1.38 1.22-1.56 
Association between AF and cognitive 
impairment 
9 1.50 1.18-1.91 
AF and cognitive impairment independent of 
stroke 
10 1.34 1.13-1.58 
AF and cognitive impairment after stroke 7 2.70 1.82-4.00 
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Table 3.  Association of AF and silent cerebral infarctions. Results from a meta-analysis of 11 
studies with 5317 AF patients and controls (59) OR = Odds ratio 
 
Parameter N studies  OR (95% CI) 
Association of AF and silent cerebral infarction, 
MRI 
5 2.30 1.44-3.68 
Association of AF and silent cerebral infarction, 
CT 
4 3.45 2.03-5.87 
Prevalence of silent cerebral infarction in AF 
patients, MRI 
9 0.40 
(40%) 
0.29-0.51 
Prevalence of silent cerebral infarction in AF 
patients, CT 
6 0.22 
(22%) 
0.12-0.32 
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Table 4. Potential mechanisms underlying atrial fibrillation (AF)-associated cognitive 
impairment 
   
Association 
 
Genetic predisposition common to 
both dementia and AF 
 
 Shared risk factors (e.g. age, 
hypertension, diabetes) 
 
Causation Clinical stroke  
 Covert/silent (macro) brain infarcts 
detected by neuroimaging 
 
 Cerebral microinfarcts caused by: Microembolism 
  AF-associated prothrombotic 
state 
  AF-induced neuroendocrine 
perturbations (e.g. BNP) 
  Hypoperfusion 
  Inflammation 
 Reduced cerebral blood flow  
Epiphenomenon 
 
Treatment for AF causes cognitive 
impairment (e.g. beta-blockers) 
 
 
